100 North Main Street
United States - Map
Targacept, Inc., a biopharmaceutical company, is engaged in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates in Phase IIb clinical trials include TC-5214 to treat overactive bladder; TC-1734 for the treatment of mild to moderate Alzheimers disease; and TC-5619 for the treatment of negative symptoms and cognitive dysfunction in schizophrenia. The companys product candidates also comprise TC-6499 for the treatment for gastrointestinal disorders; TC-6987, a novel small molecule that modulates the activity of the a7 NNR; and AZD1446, a novel small molecule that modulates the activity of the a4ß2 NNR. It has a collaboration agreement with AstraZeneca AB to develop AZD1446 and earlier-stage compounds. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.
|Targacept, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Stephen A. H. Hill B.M. B.Ch. M.A. F.R.C.S.,
Chief Exec. Officer, Pres and Director
|Mr. Alan A. Musso CPA, C.M.A.,
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. & Admin., Treasurer and Assistant Sec.
|Mr. Patrick C. Rock J.D.,
Sr. VP, Gen. Counsel and Sec.
|Mr. David A. Hosford M.D., Ph.D.,
VP of Clinical Devel. and Regulatory Affairs
|Mr. Scott N. Cullison ,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|